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The most recent National Nosocomial Infection Surveillance
(NNIS) data from 2002 to 2004 show NICU VAP rates ranging
from 1.4 to 3.5 per 1,000 ventilator days (68). In 1998, a crosssectional study of hospital-acquired infections in 50 children’s
hospitals was performed by the Pediatric Prevention Network
(88). Of 43 children’s hospitals that returned questionnaires
reporting NICU and PICU surveillance data, the VAP rate by
device days was reported by 19 hospitals, and 12 hospitals
provided VAP rates stratified by birth weight groups (Table 1).
In this cross-sectional survey, VAP rates were highest for the
1,001- to 1,500-g and ⬍1,000-g birth weight categories.
Differences in study methodology and case mix can influence
the reported incidence of VAP (6). Surveillance methods differ
across study institutions, introducing variability into the reported incidence of VAP. The influence of surveillance intensity on the reported prevalence of nosocomial infections is
illustrated by a 41-month surveillance study in a children’s
hospital. Infection control surveillance was conducted twice a
week for the first 2 years of the study and then daily for the
second 2 years of the study through a nursing sentinel sheet.
Those investigators found a 50% increase in the incidence of

INTRODUCTION
Ventilator-associated pneumonia (VAP) is pneumonia in
mechanically ventilated patients that develops later than or
at 48 h after the patient has been placed on mechanical
ventilation. VAP is the second most common hospital-acquired infection among pediatric and neonatal intensive
care unit (ICU) (NICU) patients (41, 43). Overall, VAP
occurs in 3 to 10% of ventilated pediatric ICU (PICU)
patients (1, 28). Surveillance studies of nosocomial infections in NICU patients indicate that pneumonia comprises
6.8 to 32.3% of nosocomial infections in this setting (26, 39,
48). The incidence of VAP is higher in adult ICU patients,
ranging from 15 to 30% (8, 31, 50, 70, 90).
NICU VAP rates vary by birth weight category as well as
by institution. Two large studies are summarized in Table 1.
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TABLE 1. VAP rates stratified by birth weighta
Range (median) of VAP rates by birth weight (g) of:

Study
b

NNIS
Stoverc
a
b

86–102 high-risk nurseries
12 NICUs

ⱕ1,000

1,001–1,500

1,501–2,500

⬎2,500

0.0–8.5 (2.4)
0.0–21.2 (3.5)

0.0–8.0 (0.0)
0.0–34.5 (4.9)

0.0–6.1 (0.0)
0.0–13.7 (1.1)

0.0–3.2 (0.0)
0.0–6.0 (0.9)

Range given is the 10th to 90th percentile for NNIS data.
See reference 68.
See reference 88.

reported nosocomial infections following the introduction of
daily surveillance (39).
NNIS definitions for VAP were revised in 2002, resulting in
a more stringent definition of VAP. Studies of VAP incorporating these revised definitions reported lower rates of VAP,
making it difficult to know if VAP was previously overdiagnosed or is now underdiagnosed. The revised definitions must
also be considered when VAP rates are compared over time.
Applying the Centers for Disease Control and Prevention
(CDC) definitions for VAP in low-birth-weight infants introduces additional complexity in defining the incidence of VAP.
CDC definitions for VAP exist for infants ⬍1 year of age,
but there are no specific definitions for low- or very-lowbirth-weight infants. These patients often have comorbidities such as bronchopulmonary dysplasia, hyaline membrane
disease, bloodstream infections (BSIs), and necrotizing enterocolitis that obscure clinical, laboratory, and radiographic evidence of VAP.
OUTCOMES
VAP is associated with increased morbidity in PICU patients, specifically, a longer duration of mechanical ventilation.
Fischer et al. (34) performed a prospective cohort study to
determine the delay of extubation attributable to VAP among
neonates and children undergoing repair of congenital heart
disease. Twenty-six of the 272 patients enrolled over a 22month period developed VAP (9.6%). VAP diagnosis was
made when the following criteria were met: fever exceeding
38.5°C, tachypnea and/or otherwise unexplained increased oxygen requirement, elevated white blood cell count (⬎15 ⫻ 109
cells/liter), a cultured pathogen from tracheal aspirate together
with a positive gram stain, and increased leukocyte contents,
plus an infiltrate on chest radiographs persisting for 48 h or
more (29). Using a Cox proportional hazards model to control
for complexity of surgery, other respiratory complications, and
secondary surgeries, those investigators found that the median
delay of extubation attributable to VAP was 3.7 days (average
of 5.2 versus 1.5 for patients with and without VAP, respectively). VAP rates increased dramatically for patients intubated for long periods of time. Among patients extubated
within the first 3 days of surgery, only 4% developed VAP,
compared to 40% of postoperative cardiothoracic surgery patients intubated longer than 30 days (34). Of the 26 VAP cases,
19 occurred within the first 3 to 6 days after surgery.
Presumed VAP is also associated with additional resource
utilization with respect to antibiotic administration. VAP is the
most common reason for the initiation of empirical antibiotics
among PICU patients. A prospective cohort study at an aca-

demic tertiary care center performed in a PICU (n ⫽ 456)
found that over half (56.6%) of all patients (n ⫽ 258) received
antibiotics (33). Treatment for suspected VAP comprised 616
of 1,303 (47%) of the antibiotic treatment days. Those authors
reviewed medical records to determine whether patients had
evidence of an alternative explanation for the symptoms attributed to VAP, such as a viral infection. For 40% of the antibiotic days (552/1,303 treatment days), patients were classified as
having no infection (i.e., did not meet clinical criteria as defined by the CDC) or as having a viral infection. Those authors
concluded that an intervention targeted at decreasing antibiotic use for VAP would have the greatest impact on antibiotic use.
In pediatric populations, the published data are unmatched
for severity of illness and univariate but suggest that pediatric
patients with VAP may have excess mortality and length of
PICU and NICU stay. The European Multicenter Trial examined the epidemiology of hospital-acquired infections in 20
units (5 PICUs, 7 neonatal units, 2 hematology-oncology units,
and 8 general pediatric units) in eight countries, with a total of
14,675 admissions (710 admission in PICUs) (77). Those investigators found the infected patients had a longer mean
length of stay in the PICU (26.1 ⫾ 17.3 versus 10.6 ⫾ 6 days;
P ⬍ 0.001) than uninfected patients. The mortality rate was
10% for PICU patients with nosocomial infections. The mortality and length of stay associated specifically with VAP were
not reported, although VAP accounted for 53% of the nosocomial infections in PICU patients. Mortality among uninfected PICU patients was not reported. Similarly, PICU length
of stay in a 9-month prospective cohort study in an academic
tertiary care center revealed that patients with VAP (n ⫽ 30)
had a mean PICU length of stay of 27 days versus 6 days for
uninfected patients (n ⫽ 595) (P ⫽ 0.001) (28). In that same
study, the mortality rates with and without VAP were 20% and
7%, respectively (P ⫽ 0.065). Outcomes between patients on
mechanical ventilation for more than 8 days with VAP (n ⫽ 30)
and those without VAP (n ⫽ 62) were also compared. PICU
length of stay was longer for VAP patients (27.53 ⫾ 20.09
versus 18.72 ⫾ 35 days), as was hospital length of stay (52.63 ⫾
37.43 versus 33.77 ⫾ 49.51 days), but no differences in mortality rates for VAP (20%) or uninfected patients (21%) were
found. Almuneef et al. (1) determined in a prospective cohort
study (n ⫽ 361) that PICU lengths of stay with (n ⫽ 37) and
without (n ⫽ 324) VAP were longer for patients with VAP
(33.70 ⫾ 30.28 versus 14.66 ⫾ 17.34 days; P ⫽ 0.001). Statistically significant differences in mortality rates between
patients with VAP and those without VAP were not found (P ⫽
0.362). Both of those studies performed only univariate analyses to compare mortality rates among patients with and with-
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Recommendations for Current Practice
and Future Research
Differences in the incidence of VAP occur as a result of the
definitions used, persons doing surveillance, and frequency of
surveillance. Standardization of surveillance methodology and
validation of current definitions against a histopathologic or
microbiologic “gold standard” would make interinstitutional
comparisons meaningful, particularly in light of mandatory
reporting of health care-associated infections. Recent literature suggests that pediatric VAP is associated with increased
morbidity, antibiotic use, PICU cost, and PICU and hospital
length of stay. Prospective studies using consistent definitions
of VAP and controlling for severity of illness both at admission
and at the time of VAP as well as other possible predictors of
death and length of stay are necessary to define the true attributable mortality and cost associated with VAP in pediatric
patients.
DIAGNOSIS
Clinical Criteria
The lack of a gold standard for the diagnosis of VAP in both
adults and children makes an interpretation of the literature
complex. The clinical criteria for the diagnosis of VAP have
been established by the NNIS and the CDC (22). Patients who
are mechanically ventilated for more than or equal to 48 h
must have two or more abnormal chest radiographs with at
least one of the following symptoms: new or progressive and
persistent infiltrate, consolidation, cavitation, and/or pneumatoceles (in infants ⱕ1 year of age). However, in patients
without underlying pulmonary or cardiac disease (respiratory
distress syndrome, bronchopulmonary dysplasia, pulmonary
edema, or chronic obstructive pulmonary disease), one definitive chest radiograph is acceptable. In addition to abnormal
chest radiographs, a patient must have at least one of the
following symptoms: fever (⬎38°C) with no other recognized
cause, leukopenia (⬍4,000 white blood cells [WBC]/mm3) or
leukocytosis (ⱖ12,000 WBC/mm3), and at least two of the
following criteria: new onset of purulent sputum, change in

character of sputum, increased respiratory secretions, or increased suctioning requirements; new onset of or worsening
cough, dyspnea, or tachypnea; rales or bronchial breath sounds;
and worsening gas exchange (e.g., O2 desaturations [e.g., PaO2/
FiO2 levels of ⱕ240], increased oxygen requirements, or increased ventilation demand). The criteria described above may be
used to diagnose VAP in children; however, specific diagnostic
criteria for VAP have been developed for infants ⱕ1 year of age
and children ⬎1 and ⱕ12 years of age. Infants that are ⱕ1 year
old must have worsening gas exchange (oxygen desaturations,
increased oxygen requirements, or increased ventilator demand)
and at least three of the following criteria: temperature instability
with no other recognized cause; new onset of purulent sputum,
change in character of sputum, increased respiratory secretions,
or increased suctioning requirements; apnea, tachypnea, nasal
flaring with retraction of chest wall, or grunting; wheezing, rales,
or rhonchi; cough; and bradycardia (⬍100 beats/min) or tachycardia (⬎170 beats/min). Children ⬎1 and ⱕ12 years of age must
meet at least three of the following criteria: fever (⬎38.4°C or
⬎101.1°F) or hypothermia (⬍37°C or 97.7°F) with no other recognized cause; leukopenia (⬍4,000 WBC/mm3) or leukocytosis
(ⱖ15,000 WBC/mm3); new onset of purulent sputum, change in
character of sputum, increased respiratory secretions, or increased suctioning requirements; rales or bronchial breath
sounds; and worsening gas exchange (O2 desaturations [pulse
oximetry of ⬍94%], increased oxygen requirements, or increased
ventilation demand). NNIS/CDC criteria do not require microbiologic confirmation to diagnose pneumonia.
In summary, many of the diagnostic criteria are similar for
the ⱕ1-year-old and ⬎1- or ⱕ12-year-old age groups. Temperature instability is a diagnostic criterion for the ⱕ1-year-old
age group; either temperature elevation or hypothermia is a
criterion for the ⬎1- and ⱕ12-year-old age group. For the
⬍1-year-old group, cough, bradycardia, tachycardia, nasal flaring, grunting, and wheezing are diagnostic criteria not listed for
the ⬎1- or ⱕ12-year-old age groups, although for the older age
group, dyspnea without further specific definition is a diagnostic criterion. Worsening gas exchange, change in character or
amount of sputum, cough, rales, or bronchial breath sounds
are criteria for diagnosis in all three age groups. We suggest
that a consistent use of the age-specific definitions are preferred, although we were unable to find any published studies
directly comparing the sensitivity and specificity of the agespecific definitions to those for any age group.
Clinical definitions for VAP may be applied inconsistently,
and the lack of specific definitions of components of the clinical definition such as worsening gas exchange, oxygen desaturations, increased oxygen requirements, and increased ventilator demand may exacerbate this. Cordero et al. (19)
determined differences in the application of the CDC definitions using NICU patients (n ⫽ 37) diagnosed with VAP by
interpretation of CDC definitions by infection control practitioners (ICPs) and a positive tracheal aspirate culture. A panel
of neonatologists reviewed the clinical and laboratory evidence
as well as the radiographs. The neonatologists diagnosed VAP
in only seven patients. The neonatologists categorized the
other patients as having asymptomatic airway colonization
(n ⫽ 12), BSI (n ⫽ 7), and airway colonization with equivocal
signs of infection (n ⫽ 11). Among 8 of the 11 patients with
equivocal signs of infection, the general radiologist report
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out VAP. Multivariate analysis of predictors of mortality
among PICU patients with sufficient numbers of VAP controlling for severity of illness both at admission and at the time of
VAP as well as other potential predictors of death is necessary
to determine the true attributable mortality of VAP in pediatric patients.
VAP has also been shown to increase hospital costs. The
cost of VAP was analyzed in a 2-year study of PICU patients
(n ⫽ 1919) with a single admission (38). The direct cost for
patients with VAP (n ⫽ 56) was $38,614, and that for patients
without VAP was $7,682. In a multivariate analysis controlling
for other predictors of cost including age, severity of illness,
underlying disease, and ventilator days, VAP was independently associated with a direct cost of $30,931 (95% confidence
interval [CI], $18,349 to $82,638) (38). This is a single study
from an academic tertiary care center; further studies are
needed to determine whether the results from this single center are generalizable.
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TABLE 2. Accuracy of invasive diagnostic techniques for the diagnosis of VAP in adults and childrena
No. of
patients

Adults
Rouby et al. (80)
Chastre et al. (13)
Fabregas et al. (30)

26
26
25

Protected mini-BAL
PSB
TBA
Protected BAL
BAL
PSB
Any invasive diagnostic
technique

Children
Gauvin et al. (42)

10

BAL (104 CFU/ml)

29

Bacterial index ⬎5
ICB
Endotracheal cultures
BAL (104 CFU/ml)

Labenne et al. (60)

SE
(%)

SP
(%)

Histopathology, lung tissue culture
Histopathology, lung tissue culture
Histopathology, lung tissue culture

70
100
69
39
77
62
85

69
60
92
100
58
75
50

Expert opinion; 2/3 blinded to BAL
and PSB results

50

80

78
30
90
72

86
95
40
88

69
79
90

95
88
88

Diagnostic technique

Gold standard(s)

(i) Positive pleural fluid culture, (ii)
computed tomography scan with
abscess, (iii) histopathology, (iv) lung
tissue culture, (v) blood and tracheal
aspirate positive for same organism
without other source, (vi) expert
opinion; 2/3 blinded to BAL/PSB

PSB
ICB on gram stain and ⫹ BAL
ICB on gram stain and ⫹ BAL
and ⫹ PSB
a

SE, sensitivity; SP, specificity; TBA, tracheobronchial aspirates; ICB, intracellular bacteria.

stated that the radiographic changes were suggestive of VAP;
the neonatologist panel, reviewing the same radiographs, concluded that VAP was unlikely in these patients. Those authors
concluded that an isolated positive tracheal aspirate does not
distinguish between airway colonization and VAP and that
routine radiology reports without definitive clinical and laboratory evidence may be misleading.
Invasive Testing in Adults
NNIS/CDC criteria for VAP do not require microbiologic
confirmation. A brief review of invasive testing to confirm the
diagnosis of VAP in adults will be performed, given the paucity
of literature regarding invasive testing in children. It is unclear
whether the adult experience can be extrapolated to children.
Several studies have examined the accuracy of invasive testing
for the diagnosis of VAP in critically ill adults (Table 2).
Microbiologic examination of specimens obtained from bronchoalveolar lavage (BAL) or protected specimen brush (PSB)
have an estimated 70% sensitivity and 77% specificity compared to histopathology and/or lung tissue culture (13, 30, 80).
In one of the most comprehensive studies of VAP in mechanically ventilated adults, Rouby et al. (80) sought to describe the histologic and bacteriologic characteristics of human
nosocomial pneumonia and to evaluate the accuracy of protected mini-BAL for the diagnosis of VAP compared to lung
tissue cultures and lung histology in patients who died while on
mechanical ventilation. Twenty-six patients had both positive
pathology and lung tissue culture; in 20 of these patients, the
BAL and lung tissue culture results were concordant (Fig. 1).
Chastre (13) compared the accuracy of the bronchoscopic

PSB to that of histologic and bacteriologic examinations of
pulmonary specimens in adults (n ⫽ 26). PSB and lung cultures
were highly correlated (r ⫽ 0.65; n ⫽ 28; P ⬍ 0.001) and higher
in patients not on antibiotics within 1 week before death than
in patients on antibiotics before death (r ⫽ 0.55; n ⫽ 33; P ⬍
0.001). Pneumonia was not found by histology or lung tissue
culture when PSB culture organisms were ⬍103 CFU per ml.
PSB cultures with ⱖ103 CFU/ml identified all patients with
histologically proven pneumonia. In patients treated with antibiotics, four patients had microorganisms isolated by PSB
with concentrations of ⬎103 CFU/ml not found in the lung
tissue cultures.
Fabregas and colleagues (30) sought to determine the accu-

FIG. 1. Comparison of protected minibronchoalveolar lavage with
histopathology and bacteriology for diagnosing VAP.
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Invasive Testing in Children
A few studies have examined the sensitivity and specificity of
lower airway sampling in PICU patients and found the sensitivity and specificity of BAL (104 CFU/ml) to be 50 to 72% and
80 to 88%, respectively (42, 60) (Table 2). The nonbronchosopic BAL (NB-BAL) has been used in children as an alternative
to fiberoptic BAL to diagnose pneumonia. This procedure is
performed by placing a suction catheter into the endotracheal
tube until resistance is met and then placing and suctioning
back a small amount of sterile normal saline from the lower
airway. The presence of bubbles in the returned fluid is suggestive that a lower airway sample containing surfactant has
been obtained. Quantitative cultures of the fluid are then performed by the microbiology laboratory. This procedure may be
advantageous compared to fiberoptic bronchoscopic techniques because bronchoscopic equipment is not required, a
trained bronchoscopist is not necessary, and the diagnostic
accuracy is comparable to that of fiberoptic techniques (36,
37, 71).
Gauvin et al. (42) performed a 27-month prospective cohort
study of PICU patients suspected of having VAP in a tertiary
academic care center. Of 30 patients, 10 were diagnosed with
VAP and 9 were diagnosed with ventilator-associated tracheitis by an expert panel. The expert panel was used as the
reference standard; they were given clinical, radiographic, and
microbiologic data but were blinded to the BAL results. A
bacterial index (sum of the log of all species obtained from
BAL) of ⬎5 had the highest correlation with the reference
standard (concordance, 83%; kappa ⫽ 0.61), a sensitivity of
78%, a specificity of 86%, a positive predictive value of 70%,
and a negative predictive value of 90% (42). Intracellular bacteria and gram stain from BAL were specific (95% and 81%,
respectively) but not sensitive (30% and 50%, respectively) for
the diagnosis of pediatric VAP, whereas clinical criteria and
endotracheal cultures were sensitive (100% and 90%, respec-

tively) but not specific (15% and 40%, respectively). That study
concluded that blind BALs with a bacterial index of ⬎5 are the
most reliable method for diagnosing VAP in mechanically ventilated children. The study did not describe what proportion of
patients were on antibiotics or the duration of antibiotic exposure prior to BAL.
Labenne et al. (60) also investigated the sensitivity and specificity of PSB and BAL in PICU patients with suspected VAP.
The gold standards used by those investigators were a positive
pleural fluid culture, computed tomography scan with pulmonary abscesses, histopathological evidence, positive lung biopsy
(⬎104 CFU/gram), the same bacteria isolated in blood and
endotracheal aspirate without another source, or clinical diagnosis using CDC guidelines established independently by two
investigators blinded to PSB/BAL culture results. Of 103 patients, 29 were diagnosed with VAP, 10 were labeled as “uncertain,” and 64 were classified as not having VAP. Thirteen of
64 patients with negative PSB and BAL cultures had antibiotics
stopped after 48 h, 25 of 64 had negative cultures, and antibiotics were not used at all, and 28 of 38 had a positive tracheal
aspirate culture but negative PSB and BAL, so antibiotics were
discontinued prior to the standard 7-day treatment in that
center. The sensitivity and specificity for BAL fluid culture
were 72% and 88%, respectively. The intracellular bacteria
and the BAL combined had sensitivity and specificity of 79%
and 88%, respectively. Use of PSB culture results in combination with intracellular bacteria and BAL further increased the
sensitivity and specificity to 90% and 88%, respectively. The
PSB and BAL are effective methods of collecting distal samples and were helpful in diagnosing VAP. However, a combined diagnostic approach was superior to either one alone.
The safety of the NB-BAL in children has also been determined by several studies; few adverse experiences (n ⫽ 18)
have been reported (12, 42, 60, 66, 79). The types of adverse
events were sustained oxygen desaturation requiring increased
ventilatory support (n ⫽ 11), pneumothorax (n ⫽ 4), hypotension (n ⫽ 2), and significant increase in intracranial pressure
(n ⫽ 1). Of the 11 patients who experienced sustained oxygen
desaturations, 7 patients were diagnosed with acute respiratory
distress syndrome and saturations in the low 80s before the
procedure was performed. Pneumothorax occurred in patients
less than 1 month of age (n ⫽ 4). Hypotension occurred in
patients requiring dopamine before the NB-BAL procedure
began.
The safety of NB-BAL and BAL have been examined in a
study evaluating the diagnosis of infectious and interstitial lung
disease in children (n ⫽ 32) (79). That study found that both
NB-BAL and the BAL were safe, as respiratory rate, heart
rate, and oxygen saturation were monitored during the procedure and a minimum of 6 h afterwards. Patients did not require
increased supplemental oxygen after the procedure, and no
major airway bleeding occurred.
Computerized Surveillance
Recently, a retrospective study was performed to determine
the accuracy of computerized surveillance to detect nosocomial pneumonia in two NICUs over a 2-year period (n ⫽ 2,932
patients) (46). The automated monitoring system was a natural
language processor, referred to as the Medical Language Ex-
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racy of clinical criteria and microbiologic testing for the diagnosis of VAP. The clinical pulmonary infection score (CPIS)
was used to compare microbiological criteria, clinical criteria,
and sampling techniques. Lung biopsies were performed for 25
mechanically ventilated patients immediately after death. The
reference standard was the presence of positive histology for
pneumonia or positive lung cultures. Chest X-ray infiltrates
and at least two of three clinical criteria achieved sensitivity
and specificity of 69% and 75%, respectively. The CPIS sensitivity and specificity were 77% and 42%, respectively. Noninvasive and invasive techniques achieved similar results. All
diagnostic techniques combined (PSB, BAL fluid, and protected BAL fluid) achieved sensitivity and specificity of 85%
and 50%, respectively.
A meta-analysis done in 2005 (n ⫽ 628) determined whether
invasive testing altered the management and mortality of VAP
in critically ill adults (84). VAP was confirmed bronchoscopically in 44 to 69% of the patients. Overall, antibiotics were
almost three times as likely to be changed if a bronchoscopy
was performed. In a separate pooled analysis of prospective
uncontrolled trials, alteration in antibiotic prescription occurred 50% (36 to 65%) of the time. To our knowledge, no
similar meta-analyses exist for pediatric populations.
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Recommendations for Current Practice
and Future Research
The lack of a gold standard plagues all literature regarding
VAP in both adults and children. The current literature suggests that NB-BAL, BAL, and PSB are safe in older children
who do not have severe hypoxemia, increased intracranial
pressure, hemodynamic instability, or bleeding problems and
that invasive testing is sensitive and specific compared to a
reference of expert opinion. Comparison of the clinical definitions, including the age-specific definitions, with and without
invasive testing against histopathology and/or lung tissue culture would be a valuable addition to the literature. The feasibility of using NB-BAL in a general patient population and the
effect on antibiotic use remain to be determined.
Computerized surveillance has the potential for considerable time savings, particularly if electronic surveillance of the
radiographic reports could be combined with that of microbiology and vital signs and validated against the current practical
gold standard of application of CDC/NNIS definitions by an
experienced clinician who has reviewed the complete medical
record. Additional computerized surveillance studies are necessary to help further understand the impact that computerized surveillance may have on diagnosing pneumonia.
MICROBIOLOGY
Understanding the microbiology of VAP is critical for guiding decisions regarding empirical antibiotic therapy. A retrospective cohort study of the microbiologic etiology of VAP in
the ICU setting was performed in three hospital settings: a

large teaching hospital, a community hospital, and a children’s
hospital (5). The most commonly isolated organisms were similar across adult and pediatric hospitals: Staphylococcus aureus
(28.4%), Pseudomonas aeruginosa (25.2%), and other gramnegative bacilli (26.6%). The microbiologies of early-onset and
late-onset infections differed in the adult populations, but this
was not the case in the children’s hospital. Pseudomonas aeruginosa and Staphylococcus aureus were the most commonly isolated organisms in the children’s hospital. Pseudomonas aeruginosa was more common in the PICU than in the NICU (33.3%
versus 17%; P ⫽ 0.01), while Staphylococcus aureus was more
common in the NICU than in the PICU (38% versus 17.6%;
P ⬍ 0.001). A prospective cohort study of VAP in the same
NICU was performed. Most of the tracheal isolates from patients with VAP grew polymicrobial cultures; the organisms
most commonly isolated included Staphylococcus aureus
(23%), Pseudomonas aeruginosa (38.4%), Enterobacter spp.
(38.4%), and Klebsiella spp. (23%) (3). A limitation of these
studies is that the vast majority of isolates were from endotracheal aspirates rather than from invasive sampling of the lower
airway, and thus, the results may represent oropharyngeal
flora.
Two studies reported differences in the microbiologies of
early-onset and late-onset nosocomial pneumonia among children. Group B streptococci were most commonly isolated from
infants with maternally acquired pneumonia (31.8%), while
these organisms were rarely isolated in cases of late-onset
pneumonia (1.3%). The frequency of Staphylococcus aureus
increased from 2.4% of maternally acquired cases to 18.7% of
non-maternally-acquired cases of pneumonia, and Pseudomonas aeruginosa frequency increased from 2.9% of maternally
acquired cases to 12.9% of non-maternally-acquired cases of
pneumonia (43).
A 41-month prospective surveillance study of nosocomial
infections in a NICU divided pneumonia into early-onset (onset of symptoms within first 48 h of life) and late-onset (onset
of symptoms more than 48 h after birth) infections (98). There
were 35 cases of definite or probable early-onset pneumonia.
In 26 of these cases, potential pathogens were identified: 18
(76.9%) group B streptococci, 1 (3.8%) group F streptococcus,
3 (11.5%) Streptococcus pneumoniae isolates, and 2 (7.7%)
nontypeable Haemophilus influenzae infections. Late-onset
pneumonia occurred in 36 of 358 (10%) neonates who were
ventilated for over 24 h. Cultures were taken from endotracheal tubes or nasopharyngeal secretions for 41 episodes of
late-onset nosocomial pneumonia. The most commonly isolated organisms were coliform spp. (n ⫽ 18; 43.9%), Pseudomonas aeruginosa (n ⫽ 14; 34.1%), and Staphylococcus aureus
(n ⫽ 6; 14.6%).
RISK FACTORS FOR VAP IN NICU PATIENTS
In pediatric populations, the pathogenesis of VAP is not well
studied. In adult patients, aspiration of oropharyngeal secretions, inhalation of aerosols containing bacteria, hematogenous spread, and bacterial translocation from the gastrointestinal tract are all considered to be mechanisms of the
development of VAP (89).
Neonates have unique characteristics predisposing them to
nosocomial infections. These patients’ immature immune sys-
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traction and Encoding system, that converted the electronic
narrative reports to coded descriptions to identify patients with
pneumonia. The automated monitoring system was compared
to diagnosis of VAP by an ICP who performed prospective
surveillance for pneumonia using NNIS definitions. A total of
1,277 patients had chest radiographs. In NICU 1, seven cases
of VAP were identified by the ICP prospective surveillance;
five of the seven cases found by the ICP were also identified by
automated computer surveillance, which flagged an additional
61 patients with possible nosocomial pneumonia. Nine were
considered to be inappropriately flagged by a second independent ICP review. The sensitivity and specificity of the computerized surveillance were 71% and 99.8%, respectively. The
positive predictive value was 7.9%, and the negative predictive
value was ⬎99%. In NICU 2, 10 cases of VAP were identified
by the ICP; only 2 of these were flagged by the computer.
Further investigation revealed that 7 of the original 10 cases
were not flagged by the computer because the original chest
radiograph reports could not be found. Eight hundred thirtysix patients had chest radiographs performed; 84 were flagged
by the computer as VAP. The sensitivity and specificity for
NICU 2 could not be calculated. The findings of that study
indicate that computerized surveillance may be useful in
streamlining the identification of patients with possible VAP
who require a more time-consuming chart review by an ICP.
This system was not linked with microbiology reports. An unstudied area is computerized surveillance linking both radiology and microbiology reports.
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changed after the move to the new unit. Those authors did not
report any changes in infection control surveillance or diagnosis in the new nursery.
RISK FACTORS FOR VAP IN PICU PATIENTS
Several prospective cohort studies described risk factors for
pediatric VAP. In a prospective cohort study at a tertiary care
center, genetic syndrome (odds ratio [OR], 2.37; 95% CI, 1.01
to 5.46), transport out of the PICU (OR, 8.90; 95% CI, 3.82 to
20.74), and reintubation (OR, 2.71; 95% CI, 1.18 to 6.21) were
all independent predictors of pediatric VAP (28). That study
also found that primary BSIs were associated with the development of VAP, as five of the nine patients with primary BSIs
and VAP had the BSI first. Another prospective cohort study
identified prior antibiotic use (OR, 2.45; 95% CI, 1.112 to
5.405), continuous enteral feeding (OR, 2.29; 95% CI, 1.093 to
4.798), and bronchoscopy (OR, 5.04; 95% CI, 1.665 to 15.266)
as being independent predictors of pediatric VAP (1). Immunosuppressant drugs (OR, 4.8; P ⫽ 0.04), immunodeficiency
(OR, 6.9; P ⫽ 0.06), and neuromuscular blockade (OR, 11.4;
P ⫽ 0.002) were also found to be independent predictors in
another prospective cohort study (32). Torres et al. (94) identified several factors associated with increased risk of developing VAP: reintubation (OR, 4.95; 95% CI, 3.48 to 7.04; P ⫽
0.000012), gastric aspiration (OR, 5.05; 95% CI, 3.28 to 7.77;
P ⫽ 0.00018), mechanical ventilation for ⬎3 days (OR, 1.17;
95% CI, 1.15 to 1.19; P ⫽ 0.015), chronic obstructive pulmonary disease (OR, 1.89; 95% CI, 1.38 to 2.59; P ⫽ 0.048), and
positive end-expiratory pressure (OR, 1.85; 95% CI, 1.30 to
2.64; P ⫽ 0.092). In nosocomial pneumonia patients, factors
associated with increased mortality risk were a rapidly fatal
underlying condition (OR, 8.84; 95% CI, 3.52 to 22.22; P ⫽
0.0018), worsening acute respiratory failure from developing
pneumonia (OR, 11.94; 95% CI, 4.75 to 30; P ⫽ 0.0096), septic
shock (OR, 2.83; 95% CI, 1.41 to 5.78; P ⫽ 0.016), inappropriate antibiotic treatment (OR, 5.81; 95% CI, 2.70 to 12.48;
P ⫽ 0.02), and non-cardiac-surgery ICU patients (OR, 3.38;
95% CI, 1.70 to 6.71; P ⫽ 0.08) (78). Medications associated
with the development of VAP are NADP, steroids, and histamine type 2 receptor blockers (28).
Recommendations for Current Practice
and Future Research
Several factors have been identified as being risk factors for
VAP in NICU and PICU patients. Many of these factors reflect a risk for aspiration such as that which may occur during
reintubation, physical movement out of the ICU, and bronchoscopy. In addition, neuromuscular weakness and immunodeficiency may predispose a patient to VAP, as does prolonged
mechanical ventilation. A risk stratification system incorporating preventable and nonpreventable risk factors for pediatric
VAP might assist intensivists in the development of pediatric
VAP prevention bundles and methods for identifying meaningful indicators as a measure of an institution’s success at
VAP prevention. Larger, multicenter, randomized controlled
trials using a standard reference definition of VAP to test
interventions to prevent aspiration in children would be useful.
Testing the efficacy of a standardized assessment of readiness
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tems place them at increased risk for infection (24). Skin and
mucous membranes are more permeable and are less effective
barriers to infection (47). Abnormal granulocyte migration and
bacterial digestion in these patients have been demonstrated.
Additionally, decreased activity of complement, particularly
complement opsonization, occurs in newborns (40). Lastly,
hypogammaglobulinemia occurs in premature newborns. Maternal immunoglobulin G (IgG) is transported to the fetus in
the second and last trimesters of pregnancy, and fetal IgG
levels reach maternal levels by term (58). Levels of IgG are
lower in premature newborns, as maternal levels have not yet
been attained. In the initial months following birth, maternal
IgG levels drop, and it takes the infant months to produce
ample levels of IgG and other immunoglobulins.
Low birth weight has been shown to be a risk factor for the
development of nosocomial pneumonia. A 41-month surveillance study demonstrated a significant association between a
birth weight of ⬍1,500 g and a higher rate of nosocomial
pneumonia (48). However, low birth weight may be a marker
for an increased duration of mechanical ventilation. That study
was limited by the lack of a specific control for the duration of
mechanical ventilation. Apisarnthanarak et al. (3) focused on
estimated gestational age (EGA) rather than birth weight in
their 10-month-long case control study of 211 intubated NICU
patients. VAP rates were much higher in babies with an EGA
of ⬍28 weeks (19 VAP cases) than in babies with an EGA of
ⱖ28 weeks (5 VAP cases) (P ⬍ 0.001) (3). The VAP rate per
1,000 ventilator days was also higher in babies with an EGA of
⬍28 weeks (6.5/1,000 ventilator days) than in babies with an
EGA of ⱖ28 weeks (4.0/1,000 ventilator days) but was not
statistically significant (P ⫽ 0.34) (3). Not all investigators
found an inverse relationship between birth weight and frequency of nosocomial pneumonia. A prospective surveillance
study of nosocomial infections in seven Brazilian NICUs found
that the rate of nosocomial pneumonia was actually higher in
neonates with birth weights of ⬎1,500 g than in babies with
birth weights of ⱕ1,500 g (4.4/1,000 patient days versus 2.8/
1,000 patient days) (72).
Prior BSIs have been identified as a being a risk factor for
VAP in NICU patients. In babies with an EGA of ⬍28 weeks,
history of a prior BSI was the only significant risk factor for the
development of VAP in multivariate analyses after controlling
for the duration of mechanical ventilation (P ⫽ 0.03). Although none of the cases of VAP were caused by the same
organism as that which caused the BSI, those authors suggested that prior BSI may serve as a surrogate for severity of
illness rather than actually contributing to VAP (3).
The design of the NICU may also have an effect on the
incidence of nosocomial infections and specifically VAP. A
5-year prospective study of nosocomial infections in a NICU
was performed (44). Midway through that study, the NICU
location was moved from cramped quarters adjacent to a busy
medical ward to a new facility. The new nursery had a 50%
increase in staffing and improved infection control features. In
the old nursery, 16 of 492 patients had pneumonia, whereas
in the new nursery, only 1 patient of 419 had pneumonia. While
the new nursery had improved structural infection control
measures such as more space per patient, a large number of
sinks, and a separate isolation room, it is not clear if other
practices of care, such as head-of-bed elevation or suctioning,
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to wean mechanical ventilatory support would also be useful in
this patient population, as would a standardized assessment of
pain and the need for sedation and neuromuscular blockade.
PREVENTION

Head-of-Bed Elevation
Supine position has been associated with VAP in adult patients, which is thought to be related to an increase in gastroesophageal reflux and aspiration. Semirecumbent positioning
has been demonstrated to decrease surrogate outcomes such
as aspiration and gastroesophageal reflux in adults (16), and
one clinical trial demonstrated a dramatic decrease in the
incidence of confirmed VAP in patients with head-of-bed elevation (5% versus 23%; OR, 6.8; 95% CI, 1.7 to 26.7) (25). The
efficacy of semirecumbent positioning in preventing VAP in
children has not been established. One age- and sex-matched
case control study of nosocomial pneumonia in children found
that head-of-bed elevation did not differ between cases and
controls. That study was limited by small numbers of cases
and controls (n ⫽ 9 for each group) (10). Additionally, sizerelated factors must be considered in the utility of semirecumbent positioning in children. For instance, elevating the head
⬎30° is logistically challenging for small pediatric patients such
as infants and toddlers.
In-Line Suctioning
Endotracheal suctioning is used for eliminating bronchopulmonary secretions from the airway. Traditional open endotracheal suction requires disconnection from the ventilator. This
process has been shown to result in increased intracranial
pressure, increased mean blood pressure, and hypoxia in mechanically ventilated children (27, 57). The introduction of a
closed multiuse suction catheter in the 1980s allowed endotracheal suctioning without disconnection from the ventilator. In
critically ill adult populations, closed suction systems have
been shown to result in fewer physiologic disruptions such as
arterial and venous desaturations and arrhythmias (54).
Closed endotracheal suction systems present the potential
for bacterially contaminated secretions to pool in the lumen of
the tube, with reinoculation of the respiratory tract with each
repeated suctioning. On the other hand, a closed system could
potentially decrease environmental contamination of the
respiratory device. Many studies of critically ill adults have compared the incidence of airway colonization and nosocomial
pneumonia in patients on a closed multiuse system to that in
patients on a single-use open suction system. The frequency of

airway colonization has been shown to be significantly more
frequent in patients on the closed suction system (23). However, studies have not demonstrated an increased frequency of
nosocomial pneumonia in patients on the closed suction system (23, 54). Indeed, a more recent prospective randomized
study of 102 ventilated adults demonstrated an increased risk
of VAP for patients with an open suction system compared to
a closed suction system (adjusted risk, 3.5; 95% CI, 1.0 to
12.33) (17). There are currently no CDC recommendations
regarding the preferential use of closed or open suction systems, nor are there recommendations regarding the frequency
of change for multiuse closed suctioning systems in a single
patient (89).
A single study has compared open and closed suction systems in critically ill children. Cordero et al. (20) monitored 133
ventilated NICU patients who were alternately assigned to a
closed or open suction system for bacterial airway colonization,
nosocomial pneumonia, BSI, and bronchopulmonary dysplasia. A definition of nosocomial pneumonia required radiographic evidence of “probable” pneumonia (new airspace disease or a parenchymal process) and positive blood cultures and
tracheal culture for a respiratory pathogen. Colonization patterns from tracheal cultures were comparable between groups,
with gram-positive colonization occurring by the second week
of intubation and gram-negative colonization occurring after
the third week of ventilation. There were no significant differences in the incidences of VAP or BSIs or mortality between
patient groups. Additionally, the numbers of endotracheal suctions per day, the numbers of reintubations, the incidences and
severities of bronchopulmonary dysplasia, and the numbers of
infants discharged on supplemental oxygen were similar between groups. Finally, 40 of 44 (91%) NICU nurses judged the
closed suction system to be easier to use, less time-consuming,
and better tolerated by NICU patients.
H2 Blockers/Sucralfate
The acidification of gastric contents is thought to decrease
colonization with potentially pathogenic bacteria. Stress ulcer
prophylactic medications that increase gastric pH, like H2antagonists and antacids, may increase colonization with
pathogenic organisms and increase the risk of VAP (18).
Sucralfate is an alternative stress ulcer prophylactic agent that
does not alter gastric pH, and this medication may lower the
risk of VAP while maintaining stress ulcer prophylaxis. Over 20
clinical trials with adults have investigated the risk of VAP
associated with these medications. Of seven meta-analyses of
these clinical trials, four found a significant reduction in the
incidence of VAP in patients treated with sucralfate compared
to patients receiving H2 antagonists. The same effect occurred
in the other three analyses but did not reach statistical significance. Three of these meta-analyses demonstrated a significant reduction in mortality associated with sucralfate therapy
(16).
Two clinical trials compared the risk of VAP with various
methods of stress ulcer prophylaxis in pediatric patients. A
retrospective study included 155 PICU patients who had a
nasogastric tube in place and were mechanically ventilated for
⬎48 h: 54 were given ranitidine, 53 were give sucralfate, and 48
were not on stress ulcer prophylaxis (62). There was no signif-
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Several recommendations have been given to decrease VAP.
The CDC and Healthcare Infection Control Practices Advisory
Committee suggest using orotracheal tubes (instead of nasotracheal tubes) when patients require mechanical ventilation,
changing breathing circuits of ventilators only if they malfunction or if they are visibly contaminated, and using endotracheal
tubes with dorsal lumens to allow respiratory secretions to
drain (89). There are no recommendations for the preferential
use of sucralfate, histamine 2 receptor antagonists, or antacids
for stress bleeding prophylaxis (89).
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Hand Hygiene
Efforts at reducing person-to-person transmission of bacteria are crucial for preventing nosocomial infections. Significant
bacterial contamination of hospital employees’ hands during
routine patient care has been demonstrated (75). The concept
that routine hand washing by health care workers reduces
nosocomial infections is not new, but the first study investigating the impact of hand hygiene on the rate of hospital-acquired
infections in NICU patients was recently performed (99). A
2-year-long multimodal intervention was instigated, which consisted of formal lectures, written and posted instruction regarding proper hand hygiene technique, covert observation, financial incentives, and regular feedback of observed hand hygiene
rates. Surveillance of hand washing compliance and nosocomial infections from the pre- and postintervention periods

were compared. The rate of hand hygiene compliance increased from 43% at baseline to 80% during the intervention,
and the rate of respiratory infections decreased from 3.35 to
1.06 per 1,000 patient days (P ⫽ 0.002) in the pre- and postintervention periods. The two parameters were statistically correlated (r ⫽ ⫺0.385; P ⫽ 0.014). That study is helpful in
demonstrating an association of hand hygiene and prevention
of nosocomial pneumonia, but it has limitations. The beforeafter design of the study makes it difficult to assess if a reduction in the rate of pneumonia is attributable exclusively to the
increase in hand hygiene. An intervention of this magnitude
may have altered other clinical practices related to the spread
of bacterial contamination, as employees’ awareness of preventing nosocomial infections was increased. Those authors
did point out that no changes in the use of surfactant or suction
procedures occurred during the study period but did not comment on other procedural changes that may have occurred
such as head-of-bed elevation, stress ulcer prophylaxis, or oral
hygiene changes. Additionally, while rates of hand hygiene
compliance remained at 81% during the 16-month postintervention period, it is unclear how sustainable this effect was
after observations were discontinued.
A prospective study of a 3-month-long implementation of an
intervention to decrease rates of nosocomial infection in NICU
patients was undertaken (69). The intervention consisted of
three parts: (i) grouping of all blood-taking tasks to reduce the
number of daily blood draws, (ii) reducing the frequency of
blood investigations after stabilization of acute illness, and (iii)
using an aseptic delivery system of drugs though a central
venous catheter to reduce peripheral intravenous access. The
incidences of nosocomial infection in the NICU between the
1-year preintervention period and the 1-year postintervention
period were compared. VAP rates declined from 3.3/1,000
ventilator days to 1.0/1,000 ventilator days after the intervention. Again, that study was limited by the before-after nature of
the design. Those authors acknowledged that practices regarding mechanical ventilation also changed during the study period, as patients were weaned from the ventilator more aggressively and as soon as possible. Earlier weaning may have
contributed to lowering the VAP rates, as prolonged intubation is a risk factor for VAP in children (62).
The importance of hand hygiene in preventing horizontal
transmission of pathogens among mechanically ventilated patients was highlighted by a study performed by Sole et al. (86)
to evaluate the proportion of suctioning devices colonized with
pathogenic bacteria and to correlate the bacteria found on
respiratory equipment with those found in patients’ mouths
and sputum. Those investigators found that within 24 h of
changing to new suctioning equipment, 94% of tonsil suction
tubing, 83% of in-line suction tubing, and 61% of distal suction
connectors were colonized with pathogenic bacteria similar to
those found in the patients’ oropharynx and sputum (86).
Selective Decontamination
The impact of using topical antibiotics on tracheostomy sites
on exogenous colonization or infection of the lower airways
has been studied. A 2-year-long prospective observational cohort study was performed with 23 children who were treated
with 2% paste of polymyxin E and tobramycin on the trache-
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icant difference in the incidences of VAP between patients
treated with ranitidine and patients treated with sucralfate
(11.1% versus 7.5%; 2 ⫽ 0.40; P ⫽ 0.52). That study had
several limitations. Patients were not randomized into study
groups, and patient characteristics differed between patients
given stress ulcer prophylaxis and those who were not given
prophylaxis. The retrospective nature of the study may have
resulted in errors in diagnosing VAP.
A prospective study was performed to study the incidence of
VAP and associated mortality among patients randomized to
one of four groups for stress ulcer prophylaxis in Turkey (101).
That study included 160 PICU patients: 38 received sucralfate,
42 received ranitidine, 38 received omeprazole, and 42 did not
receive prophylaxis. VAP occurred in 70 of 160 (44%) patients,
ranging from 41 to 48% in individual treatment groups. There
was no difference in the incidence of VAP across treatment
groups. The overall mortality rate was 35 of 160 (22%) and did
not differ significantly among treatment groups, ranging from
21 to 23% across groups. The overall incidence of VAP (44%)
in this study was much higher than that reported in other
pediatric studies from referral hospitals (5.1% to 10.2%) (1,
28). It is possible that VAP was overdiagnosed in that study,
although diagnostic criteria used in that study were similar to
criteria used in this country. If VAP was overdiagnosed, this
effect would likely be distributed throughout all study groups.
That study may also have been underpowered to detect differences in the incidences of VAP among these patient groups.
Both of those studies failed to demonstrate a difference in
the incidence of VAP in patients treated with sucralfate compared to those treated with agents that alter gastric pH. Additionally, neither study demonstrated an increased risk of
VAP in patients treated with agents that alter gastric pH compared to that in patients with no treatment. The microbiologies
of infections were similar across treatment groups, and many
infections were caused by organisms that are not likely to be
affected by stress ulcer prophylaxis. It is possible that the study
sizes presented were simply too small to appreciate a significant difference in the incidence of VAP, or it is possible that
stress ulcer prophylaxis is not associated with VAP in the
pediatric population. Larger prospective randomized studies of
children are needed to asses the impact of stress ulcer prophylaxis on VAP and whether sucralfate has a protective effect
compared to medications that decrease gastric acidity.
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body site, patients in the treatment group had a significantly
lower frequency of pneumonia (2.6% versus 7.2%). In multivariate analyses, SDD retained a protective effect against
pneumonia (OR, 0.21; 95% CI, 0.06 to 0.8). There was no
significant difference in overall mortality between the treatment and control groups (six versus five patients). Patients in
that study were randomized and were well matched for most
variables with the exception of severity of illness; the treatment
group had more severely ill patients. This difference in severity
of illness would be expected to skew the results toward the null
hypothesis, but there were actually fewer cases of pneumonia
in the more severely ill group who were treated with SDD.
A prospective, randomized, double-blinded study was performed to determine the efficacy of SDD in preventing nosocomial infections in severely burned (⬎30% total body surface
area) PICU patients (7). Patients were randomized to the
treatment group (n ⫽ 11) or control group (n ⫽ 12). The
treatment group was given a mixture of polymyxin E, tobramycin, and amphotericin B four times daily by nasogastric
tube. No significant differences regarding demographics, underlying conditions, inhalation, injury, or percent of surface
area burned between patient and control groups existed. There
was no difference in the proportion of patients with colonization of wounds, feces, nasogastric aspirates, or sputum between
groups at the start of the study or throughout the study. No
significant differences between groups were noted with regard
to the serious complications measured: sepsis, pneumonia, gastrointestinal bleeding, respiratory distress syndrome, and mortality. The group treated with SDD had a higher incidence of
diarrhea than the control group (82% versus 17%; P ⫽ 0.003).
Results from that study suggest that SDD may not prevent
nosocomial infections in pediatric patients. However, that
study was limited by a small sample size (n ⫽ 23). Additionally,
results of that study may not be generalizable to all PICU
patients, as that study was restricted to burn patients.
A prospective nonrandomized cohort study was performed
to determine the impact of SDD on nosocomial infections in
NICU patients (49). The decision to administer decolonization
was left to attending physicians. Investigators later determined
if patients had received well-performed decolonization (decolonization within the first 5 days with oral polymyxin E,
tobramycin, and nystatin), incorrect decolonization (started
after 5 days or less than three drugs used), or no decolonization. The incidence of nosocomial respiratory infection was
lower in patients given well-performed (2.5%) or incorrect
(7%) decolonization (P value not given). Interestingly, the
incidence of nosocomial respiratory infection was lowest in
patients who were not decolonized (1%). However, because
patients were not randomized into treatment groups, significant underlying differences between groups, including gestational age, birth weight, NICU length of stay, exposure to
central catheters, and respiratory support, existed. To control
for these differences, investigators performed logistic regression and found that well-performed selective intestinal decolonization exerted a protective effect toward nosocomial infections of intestinal origin (OR, 0.17; 95% CI, 0.03 to 0.83). This
group of infections included respiratory tract infections, sepsis,
surgical wound infections, and urinary tract infections. The
investigators did not supply a separate analysis of the impact of
SDD on respiratory infections alone.
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ostoma four times a day for the first two postoperative weeks
(65). Only 1 of 23 (4%) patients developed exogenous colonization or infection of the lower respiratory tract, which was
lower than that in historical controls (6/22 [27%]). While topical antibiotics may be useful in preventing exogenous colonization or infection of the lower airways in children with tracheostoma, the risk of endogenous colonization remains high.
Endogenous colonization or infection occurred in 15 episodes
in 14 of 23 (61%) patients during the 2-week postoperative
period.
Many investigators have studied the efficacy of selective digestive tract decontamination (SDD) in preventing VAP. SDD
traditionally consists of a regimen of topical antimicrobials
applied to the oropharynx and through a nasogastric tube, with
the aim of reducing the burden of pathogenic bacteria in aspirated secretions. While the majority of trials have focused
exclusively on the use of topical antimicrobials, many have also
used a short course of intravenous antimicrobial therapy.
Seven meta-analyses of randomized, controlled trials of SDD
in adults all showed a significant reduction in the risk of VAP,
and four of those analyses also demonstrated a significant
reduction in mortality in patients treated with SDD (16). One
recent meta-analysis divided trials into those that used topical
antibiotics alone and those that used a combination of topical
and systemic antimicrobials for the prevention of nosocomial
respiratory infections (61). That analysis included 32 randomized, controlled trials including a total of 5,185 adult patients.
A protective effect was demonstrated in trials comparing patients on a combination of systemic and topical antibiotics with
controls (OR, 0.35; 95% CI, 0.29 to 0.41) and in trials comparing patients on topical antibiotics alone with controls (OR,
0.52; 95% CI, 0.43 to 0.63). A significant reduction in mortality
was seen only in trials that used a combination of topical and
systemic therapy (OR, 0.78; 95% CI, 0.68 to 0.89). Mortality
from VAP was not reduced when topical therapy alone was
used (OR, 0.97; 95% CI, 0.81 to 1.16).
Recent evidence suggests that results from some of those
trials may be overly optimistic. A meta-analysis of 32 primary
trials of SDD was performed to assess the impact of study
methodology on results (97). Study methodology was evaluated based on allocation and concealment, patient selection,
patient characteristics, blinding, and definition of nosocomial
pneumonia. That analysis found an inverse relationship between the methodologic quality and benefit of SDD on the
incidence of pneumonia, suggesting that the benefit of SDD
for the prevention of VAP may be overestimated by many
clinical trials (97).
Studies focusing on the use of SDD to prevent VAP in
children have conflicting results. A prospective study of SDD
in 226 PICU patients randomized study subjects into a treatment (n ⫽ 116) or control (n ⫽ 110) group (81). The treatment
group received colistin, tobramycin, and nystatin orally or
through a nasogastric tube every 6 h, and patients were monitored for the development of nosocomial infection in any body
site. There were 87 episodes of any nosocomial infection in 65
of 226 (28.8%) patients. The most common nosocomial infections were catheter-related bacteremia, sepsis, pneumonia, and
urinary tract infection. The overall incidence of nosocomial
infection across all sites did not differ between treatment and
control groups. However, when infections were studied by
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cance (OR, 0.42; 95% CI, 0.16 to 1.06; P ⫽ 0.07). ICU length
of stay and duration of mechanical ventilation did not differ
between the groups. Mortality was not significantly different
between the two groups (OR, 0.77; 95% CI, 0.28 to 2.11; P ⫽
0.6). The magnitude of the protective OR is striking, as is the
proximity of the CIs to statistical significance, suggesting that
additional studies with larger sample sizes might demonstrate
a significant protective effect from oral chlorhexidine rinses. Of
note, patients in those studies received either a 0.12% chlorhexidine rinse twice a day (n ⫽ 914) or 0.2% chlorhexidine gel
three times a day (n ⫽ 288).
A meta-analysis of seven randomized controlled trials (n ⫽
1,650 patients) performed by Chlebicki and Safdar (15) revealed a similar protective effect with a relative risk (RR) of
0.74 (95% CI, 0.56 to 0.96; P ⫽ 0.02) using a fixed-effects
model and a RR of 0.70 (95% CI, 0.47 to 1.04; P ⫽ 0.07) using
a random-effects model for patients treated orally with chlorhexidine. The risk reduction was even higher in cardiac surgery
patients (RR, 0.41; 95% CI, 0.17 to 0.98; P ⫽ 0.04) (15).
The Bundle Approach
In December 2004, the Institute for Healthcare Improvement (IHI) challenged hospitals to save 100,000 lives by June
2006 (21). One of the six evidence-based guidelines to be
implemented was the prevention of VAP. The VAP bundle for
adults is to (i) avoid/decrease endotracheal intubation and
duration of mechanical ventilation whenever possible, (ii) use
orotracheal and orogastric tubes to decrease the risk of hospital-acquired sinusitis, (iii) avoid heavy sedation and neuromuscular blockade with depression of cough reflexes, (iv) maintain
endotracheal cuff pressures to greater than 20 cm water, (v)
prevent condensate in tubing from entering the lower respiratory tract, (vi) maintain head-of-bed elevation at 30° to 45°,
(vii) maintain oral care, and (viii) maintain hand hygiene
(21, 67).
The team approach using the IHI bundle has been shown to
be successful in reducing VAP (21). The bundle approach has
been used at the Children’s Hospital in Boston and at Vanderbilt Children’s Hospital. In the latter, an education and intervention termed “ZAP VAP” was put into practice, with their
efforts emphasizing the IHI bundle (21). Prevention included
hand washing, elevating the head of the bed 30° to 45°, monitoring gastric residuals every 4 h to prevent aspiration, providing aggressive oral care (and documentation) every 2 h,
managing hypopharyngeal secretions, providing in-line endotracheal suction, and providing equipment care. During the
first 6 months of implementation, the time between VAP occurrences has nearly tripled.
Educational Interventions
Identifying effective measures for preventing VAP is only as
useful as the proper implementation of these measures in the
clinical setting. Many studies have shown a reduction in rates
of VAP following initiatives to educate health care workers
about the epidemiology of VAP and infection control measures used to prevent VAP (89). Most of those studies were
performed in the adult ICU setting. A recent educational intervention was performed in an integrated health system, with
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The CDC suggests that health care facilities develop and
implement a comprehensive oral hygiene program for patients
in acute-care settings or residents in long-term care facilities
who are at high risk for health care-associated pneumonia (89).
Fitch et al. (35) demonstrated that an oral care protocol and
scores developed by a dental hygienist could be used by ICU
nurses to improve oral health in critically ill adult patients.
Mean oral inflammation scores were significantly lower after
the implementation of a standard oral care protocol using
toothpaste, antibacterial mouthwash, and oral gel (3.9 [standard error of the mean, 3.0] versus 12.4 [standard error of the
mean, 2.2]; P ⫽ 0.03). Those investigators also noted lower
mean scores for oral candidiasis, purulence, bleeding, and
plaque, but the differences were not statistically significant.
The dental hygienist and nurses’ assessments had a high degree
of interrater reliability (kappa ⫽ 0.64). The scores used in that
study were developed by one of the investigators and reviewed
by other dental faculty members but were not validated in
other patient populations. In addition, those investigators did
not examine the effect of the standard oral care protocol on the
incidence of VAP or bacterial oropharyngeal colonization.
Bergmans et al. (9) performed a prospective, randomized,
placebo-controlled, double-blind study in adult ICU patients
to determine if VAP was preventable by the modulation of
bacterial flora in the oropharynx. Those investigators compared topical prophylaxis to the buccal cavities with 2% each
gentamicin, colistin, and vancomycin (n ⫽ 87) to an Orabase
placebo group (n ⫽ 78) (group A) and a second control group
of patients admitted to an ICU where no topical preparation
was used (n ⫽ 61) (group B). Topical prophylaxis eradicated a
significantly higher proportion of organisms present on admission in the oropharynx in the treatment group than in either
control group (75% of the treatment group versus 0% in the
placebo group and 9% in the no-preparation ICU group; P ⬍
0.00001). Topical prophylaxis was also effective in eradicating
organisms from the trachea (treatment group, 52%; group A,
22%; group B, 7% [P ⱕ 0.03]). The incidence of VAP was also
lower in the treatment group (10%) than in the controls (group
A, 31% [P ⫽ 0.001]; group B, 23% [P ⫽ 0.04]). That study
concluded that preventing oropharyngeal colonization is protective against VAP, with an absolute risk reduction of 0.21
(95% CI, 0.09 to 0.33); treating five patients with topical antibiotics would prevent one case of VAP. VAP was defined
prospectively using CDC definitions and confirmed with BAL
or PSB. However, it is unclear whether the person who determined whether the patients had VAP was blinded to the treatment group. In addition, the treatment group received enteral
feeds more frequently than controls, which could alter oropharyngeal flora. The placebo group (group A) was significantly
more likely than the treatment group to receive sucralfate,
another potential confounder of oropharyngeal colonization.
Pineda et al. (73) performed a meta-analysis to determine if
oral chlorhexidine treatment reduced the incidence of VAP.
Four randomized controlled trials including 1,202 patients met
inclusion criteria for the meta-analysis. Patients in the chlorhexidine treatment group were less likely to develop VAP than
those in the control group (4% [24 of 587] versus 7% [41 of
615]), although the difference did not reach statistical signifi-
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efficacy, and (xii) avoidance of overcrowding, understaffing,
and excessive workload (74). The diversity of these factors
emphasizes the need for a multipronged and continuous approach necessary to maintain high levels of compliance with
infection control measures.
A summary of interventional measures to decrease the incidence of VAP in children is provided in Table 3.
Recommendations for Current Practice
and Future Research
There is scant literature regarding testing the efficacy of
head-of-bed elevation, in-line suctioning, and preferential use
of sucralfate over histamine type 2 receptor antagonists in
pediatric VAP prevention. However, head-of-bed elevation
and other measures to prevent aspiration, a consistent approach to oral hygiene, meticulous hand hygiene, and regular
assessment of readiness to wean are biologically plausible as
effective VAP prevention measures in children. Further studies
documenting that head-of-bed elevation in children decreases
aspiration and risk of pneumonia as well as determining the
natural history of aerodigestive tract colonization and its relationship to gastric acidity in children may shed light on the
risk/benefit ratio of sucralfate and/or H2 blockers and the number needed to treat to prevent pediatric VAP.
VAP TREATMENT
Treatment of suspected VAP is centered on an approach of
initial empirical therapy with broad-spectrum antibiotics followed by de-escalation to specific antimicrobial therapy once
culture results are known or discontinuation of antibiotics if
VAP is no longer suspected. The American Thoracic Society
and Infectious Disease Society of America have recently published an updated version of their evidence-based guidelines
for the management of VAP in adults (2). Key recommendations in the new document include the use of early, appropriate, and broad-spectrum antibiotics for empirical therapy; utilization of empirical antibiotics from a different class than
antibiotics that the patient has recently received; judicious use
of combination therapy in hospital-acquired pneumonia; the
potential use of linezolid as an alternative to vancomycin for
VAP caused by methicillin-resistant Staphylococcus aureus
(MRSA); the use of colistin for patients with VAP caused by
carbapenem-resistant Acinetobacter species; the potential use
of aerosolized antibiotics as adjunctive therapy for patients
with VAP caused by certain antibiotic-resistant organisms; deescalation of antibiotics based on patients’ culture results and
clinical improvement; and a shorter duration of antibiotics for
patients with uncomplicated health care-associated pneumonia
from bacteria other than nonfermenting gram-negative bacilli.
These guidelines are based on data from clinical trials of hospital-acquired pneumonia in adult patients. There have been
few clinical studies regarding the optimal treatment for VAP in
children.
Empirical Therapy
The importance of prompt initiation of appropriate empirical therapy for suspected VAP has been demonstrated in
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results compared across a large adult teaching hospital, two
community hospitals, and a pediatric teaching hospital (4). The
targeted health care workers were respiratory care practitioners and nursing staff working in the ICU setting. This intervention centered on a 10-page self-study module that focused
on multiple aspects of VAP and also included posters, fact
sheets, and in-services for nursing staff and respiratory therapists. VAP rates between the 12-month preintervention period
and the 18-month postintervention period were compared.
Nursing compliance rates were highest among nurses at the
pediatric hospital (100%) and one of the community hospitals
(98.9%). The adult teaching hospital and the other community
hospital had significantly lower compliance rates among nurses
(64.9% and 44.2%; P ⬍ 0.001). Three hospitals had a significant drop in the VAP rates from the preintervention period to
the postintervention period. The VAP rate at the pediatric
hospital fell 38%, from 7.9 episodes to 4.9 episodes per 1,000
ventilator days (P ⬍ 0.001). The community hospital with no
change in the rate of VAP had the lowest compliance of
respiratory therapists compared to the other three hospital
combined (56.3% versus 95.2%; P ⬍ 0.001).
Not all lapses in infection control measures result from a
lack of knowledge. A survey of NICU health care workers was
performed to investigate the knowledge, beliefs, and practices
regarding nosocomial infections and infection control measures (56). The survey revealed some areas in which health
care workers’ actions arose from unawareness of data related
to infection control. For instance, few participants believed
that nosocomial infections were related to health care workers’
rings (40%), artificial fingernails (61%), or long fingernails
(48%). However, that study also revealed some disconnects
between knowledge and practice. Although 96% of respondents believed that using sterile techniques for catheter insertion and care reduces a patient’s risk for BSI, only 67% reported using full sterile barriers at least 76% of the time when
participating in inserting a line. Likewise, 91% of participants
believed gloves are important for preventing the spread of
nosocomial infections, but only 53% reported changing their
gloves in all indicated situations. That study demonstrated the
need for increased educational efforts to bridge the gaps in
knowledge of infection control recommendations. Additionally, the study demonstrated that a lack of knowledge alone
does not account for the lapses in infection control practices in
the NICU studied. The most common barriers to infection
control perceived by respondents included logistics (54%),
time (48%), and lack of supplies (47%).
Interventions that lower rates of VAP may have temporary
effects, with VAP rates eventually rising following the conclusion of the intervention, indicating the need for continuous
reinforcement of interventional measures (55). Factors associated with noncompliance with hand hygiene exist at the individual, group, and institutional levels (74). A proposed framework for the promotion of hand hygiene includes 12 factors: (i)
education, (ii) routine observation and feedback, (iii) engineering controls, (iv) patient education, (v) reminders in the
workplace, (vi) administrative sanctions and rewards, (vii)
change in hand hygiene agents, (viii) promotion of workers’
skin care, (ix) active participation at the individual and institutional level, (x) maintenance of an institutional safety climate, (xi) enhancement of individual and institutional self-
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TABLE 3. Summary of interventions to prevent VAPa
Intervention and source
(reference)

Patient description

Lopriore et al. (62)

Prospective active
surveillance
Retrospective case control

361 PICU patients(37 with VAP,
324 without VAP)
155 PICU patients (13 with VAP,
142 without VAP)

Cases had higher frequency of enteral feeds
(48.6% vs 26.8%; OR, 2.58; P ⫽ 0.006)
No significant difference between cases and
controls (53.8% vs 43.6%)

Motility agents
Lopriore et al (62)

Retrospective case control

155 PICU patients (13 with VAP,
142 without VAP)

Cases had higher frequency of motility agent
use (P ⬍ 0.05) (association not significant
in logistic regression)

Matched case control
study

18 PICU patients (9 with VAP,
9 without VAP)

No significant difference between cases and
controls in head-of-bed elevation

Prospective, randomized

133 NICU patients (67 closed,
66 open)

No difference in diagnosis of nosocomial
pneumonia between groups (n ⫽ 5
patients each)

Prospective, randomized,
double-blinded
Prospective, randomized,
nonblinded

23 burn patients (11 SDD,
12 placebo)
226 PICU patients (116 with SDD,
110 without SDD)

Prospective cohort,
nonrandomized

536 neonates (58 WP SID,
88 IP SID, 392 no SID)

No difference in rates of pneumonia (1 case
in SDD group, 0 in placebo group)
SDD protective toward respiratory infection
in logistic regression (OR, 0.21; 95% CI,
0.06–0.8)
WP SID protective toward NI of intestinal
origin in logistic regression (OR, 0.17;
95% CI, 0.03–0.83).

Retrospective case control

155 PICU patients (54 ranitidine,
53 sucralfate, 48 no prophylaxis)

Prospective, randomized,
nonblinded

160 PICU patients (38 sucralfate,
42 ranitidine, 38 omeprazole,
42 no prophylaxis)

Prospective study of hand
hygiene campaign

NICU patients admitted during
hand hygiene campaign

Prospective study of
educational intervention

PICU patients at pediatric
teaching hospital

Prospective surveillance

493 NICU patients (227 before
period, 266 after period)

Non-statistically-significant decrease in VAP
rate from 3.3 to 1.0 per 1,000 ventilator
days (P ⫽ 0.22)

Meta-analysis, seven
randomized controlled
trials

1,650 patients total (n ⫽ 812
关topical chlorhexidine兴;
n ⫽ 838 关comparator兴)

Pineda et al. (73)

Meta-analysis, four
randomized controlled
trials

1202 patients total (n ⫽ 587
关chlorhexidine group兴;
n ⫽ 615 关control group兴)

Bergmans et al. (9)

Prospective, randomized,
double-blinded, placebo
controlled
Longitudinal design,
repeated measures

87 patients (treatment group), 78
patients, (control group A), and
61 patients (control group B)
ICU nurses and dental hygienist

Topical chlorhexidine reduced VAP
incidence (RR, 0.74; P ⫽ 0.02); risk
reduction was even higher in cardiac
surgery patients (RR, 0.41; P ⫽ 0.04).
Chlorhexidine group less likely to develop
VAP (4%) compared to control group
(7%)(P ⫽ 0.07); ICU length of stay,
duration of mechanical ventilation, and
mortality not significantly different
VAP incidences were less in treatment group
(10%) than in groups A (31%; P ⫽ 0.001)
and B (23%; P ⫽ 0.04)
Nurses following oral care protocols can help
improve ICU patient oral health

Enteral feeds
Almuneef et al. (1)

Head-of-bed elevation
Black et al. (10)
Closed vs open suctioning
Cordero et al. (20)

SDD
Barret et al. (7)
Ruza et al. (81)
Herruzo-Cabrera
et al. (49)
Stress ulcer prophylaxis
Lopriore et al. (62)
Yildizdas et al. (101)

Infection control
interventions
Won et al. (99)
Babcock et al. (4)

Nursing practice (decreasing
peripheral intravenous
access)
Ng et al. (69)

Oral hygiene
Chlebicki and Safdar (15)

Fitch et al. (35)
a

Outcome

No significant difference in upper airway
colonization with GNB, no significant
difference in incidence of VAP
No significant difference in VAP between
patient groups

Rate of respiratory infections dropped
from 3.35 to 1.06 per 1,000 patient days
(P ⫽ 0.002)
38% reduction in VAP rate from 7.9 to
4.9 episodes per 1,000 ventilator days
(P ⬍ 0.001)

WP, well performed; IP, incorrectly performed; GNB, gram-negative bacilli; NI, nosocomial infection.

adults, with many studies describing higher mortality in patients who received delayed appropriate treatment for VAP
(51, 59, 63). However, inappropriate use and overuse of antibiotics can lead to increased hospital expenditures and could

potentially promote antibiotic resistance (33, 83). Empirical
antibiotic therapy for suspected VAP accounts for a major
proportion of inappropriate antibiotic use in pediatric patients,
with up to 33% of patients receiving unwarranted antimicro-
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monia were evaluated at baseline with five of the seven CPIS
items on a scale of 0 to 2 each (temperature, blood leukocytes,
tracheal secretions, oxygenation, and pulmonary radiography).
Patients with a total CPIS of ⱕ6 were considered to have a low
likelihood of pneumonia and were randomized to receive standard care as determined by their attending physician or experimental therapy with ciprofloxacin monotherapy. All patients
were reevaluated at 3 days, and of those with CPIS remaining
at ⱕ6, 100% of patients in the experimental arm had a cessation
of antimicrobial therapy, compared to 4% of patients in the standard therapy arm. There was no difference in mortality or length
of stay between treatment groups; antibiotic resistance, superinfections, or both occurred more frequently in patients receiving
standard therapy than patients receiving experimental therapy
(35% versus 15%; P ⫽ 0.017). Replication of these results in
children could offer clinical guidelines for the rapid cessation of
empirical antimicrobial therapy for suspected VAP.
Specific Treatment
Combination therapy exposes patients to multiple antibiotics
and is more expensive; a prompt de-escalation of empirical therapy to more specific antimicrobial therapy should occur once
culture results and susceptibilities are known. Monotherapy is
recommended for patients who are not at risk for infection with
MDR pathogens and for patients infected with gram-positive
pathogens including MRSA. Additionally, patients with severe
VAP should initially be treated with combination therapy but may
be changed to monotherapy if lower respiratory tract cultures do
not identify an antibiotic-resistant pathogen (2). Agents that have
demonstrated efficacy for monotherapy in adult patients infected
with susceptible organisms include fluoroquinolones, carbapenems,
cefepime, and piperacillin-tazobactam (2).
Recent interest surrounding the substitution of linezolid for
vancomycin in the treatment of VAP caused by MRSA has
emerged. A meta-analysis of two prospective, randomized,
double-blind, multicenter, multinational trials in adults with
nosocomial pneumonia comparing clinical cure from linezolid
to vancomycin was performed (100). Patients with MRSA
pneumonia who were treated with linezolid had survival that
was significantly higher than that of patients treated with vancomycin (80.0% versus 63.5%; P ⫽ 0.03). Clinical cure rates
were also higher for patients treated with linezolid than those
treated with vancomycin (59.0% versus 35.5%; P ⬍ 0.01). Both
of these effects remained significant in logistic regression models.
A prospective, randomized, open-label, multicenter, multinational trial was performed to compare the efficacy and safety
of linezolid and vancomycin for antibiotic-resistant gram-positive bacteremia and nosocomial pneumonia in hospitalized
children (53). Among patients with nosocomial pneumonia,
patients randomized to the linezolid group were more often
mechanically ventilated (63.6% versus 10.0%; P ⫽ 0.011) and
had more multiple-lobe involvement (90.9% versus 50.0%; P ⫽
0.038). No significant difference in clinical cure was seen between patients treated with linezolid and those treated with
vancomycin. However, patients treated with linezolid appeared
to experience a faster resolution of dyspnea/tachypnea/grunting than patients with vancomycin, with fewer than 40% of
patients receiving linezolid and more than 80% of patients
receiving vancomycin demonstrating these symptoms of VAP
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bial therapy for suspected VAP (33). Prescribing patterns have
also shifted toward more expensive and broader-spectrum antibiotics in hospitalized children in recent years, with the proportion of total antibiotic expenditure used for vancomycin
increasing from 0.2% in 1984 to 17.2% in 1994. Additionally,
broad-spectrum cephalosporins accounted for 17.7% of antibiotic expenditures in 1984 and 49.6% in 1994 (96). Thus,
prescribing patterns for empirical therapy for suspected VAP
should maintain a balance between adequately covering patients who are potentially infected and minimizing unnecessary
and prolonged exposure to antimicrobials.
Infection with potentially antibiotic-resistant organisms accounts for a large proportion of VAP in adults (95). When
selecting empirical therapy, physicians should be aware of the
patient’s risk factors for infection with multidrug-resistant
(MDR) bacteria, the antibiotics that the patient has recently
received, and the local antibiotic resistance patterns. Risk factors for VAP with MDR pathogens in adults include mechanical ventilation for at least 7 days, prior antibiotic use, and prior
exposure to broad-spectrum antibiotics (imipenem, broadspectrum cephalosporins, or fluoroquinolones) (95). In children, it has been postulated that patients may be colonized
with organisms from their own preexisting endogenous flora in
response to antibiotic pressure (92). Risk factors for colonization with antibiotic-resistant gram-negative organisms in PICU
patients include younger age, increasing PRISM (pediatric risk
of mortality) score, previous PICU admissions, intravenous
antibiotic use in the past 12 months, and exposure to chronic
care facilities (91, 93). Additional special considerations for
the pediatric population include premature infants with an
increased risk of Staphylococcus epidermidis infections and immunocompromised patients with an additional need for empirical antifungal therapy (52).
Monotherapy for empirical coverage is recommended for
adult patients with early-onset VAP without risk factors for
infection with MDR pathogens, while combination therapy
should be used for coverage of potential infection with MDR
organisms or late-onset VAP based on a local antibiogram.
Additionally, patients should be treated with antibiotics differing in class from those that they have recently received in case
colonizing bacteria have developed antibiotic resistance from
previous exposures (2). No consensus guidelines for empirical
coverage of suspected VAP in children exist.
Empirical therapy should be discontinued or altered based on
culture results and clinical status. The fear that negative culture
results may have missed an infection in critically ill children often
leads to prolonged empirical antimicrobial therapy in neonates
(87). A study of late-onset sepsis evaluations in neonates was
undertaken to determine a sufficient time point for the discontinuation of empirical therapy. Those investigators found that 99%
of blood cultures were positive within 48 h, and investigators used
this finding as a basis for decreasing empirical coverage from 72 h
to 48 h for suspected late-onset sepsis in neonates. That study
examined cultures from sterile body sites only. Cultures from the
respiratory tract and the vagaries of diagnosing VAP may not
lend themselves to an easily defined time point for the discontinuation of empirical therapy in suspected VAP.
Singh et al. (85) used the CPIS to guide the duration of
empirical therapy in adults. Intensive care patients with newonset pulmonary infiltrate who were suspected of having pneu-
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Duration of Therapy
No consensus exists regarding the appropriate duration of antimicrobial therapy for VAP in adults, and the appropriate duration for proven infections in critically ill children has not been
established (45). A multicenter, randomized, controlled trial was
performed using adults with VAP to compare patients treated
with appropriate empirical therapy for 8 days to patients treated

for 15 days (14). There was no difference in mortality or recurrent
infections between groups. Among patients infected with nonfermenting gram-negative bacilli, patients treated for 8 days did have
a higher relapse rate (32.8% versus 19.0%; 13.8% risk difference;
90% CI, 7.8% to 19.7%). However, among patients who experienced recurrent infections, patients treated for 8 days were less
likely to become infected with MDR pathogens (42.1% versus
62.0%; P ⫽ 0.04). These data suggest that limiting treatment of
VAP in patients infected with pathogens other than nonfermenting gram-negative bacilli is safe and may decrease the incidence of
reinfection with MDR pathogens.
Recommendations for Current Practice
and Future Research
No consensus guidelines exist for empirical coverage of suspected VAP in children.
Empirical therapy should be discontinued or altered based on
clinical status and culture results, preferably from lower airway
samples. Patients who are severely ill and/or with previous exposure to the health care system should be treated with combination
therapy. Areas for future research in children include the efficacy
of linezolid compared to vancomycin for VAP treatment, the
duration of optimal antibiotic therapy for VAP, and validation of
the CPIS in children as well as its use in treatment decisions.
CONCLUSION
VAP is the second most common hospital-acquired infection
among PICU patients. Empirical therapy for VAP accounts for
approximately 50% of antibiotic use in PICUs. VAP is associated with an excess of 3 days of mechanical ventilation among
pediatric cardiothoracic surgery patients. The attributable
mortality and excess length of ICU stay of VAP have not been
defined in matched case control studies. VAP is associated
with an estimated $30,000 in attributable cost. Surveillance for
VAP is complex and usually performed using clinical definitions
established by the CDC. Invasive testing via BAL increases the
sensitivity and specificity of the diagnosis. The pathogenesis is
poorly understood in children, but several prospective cohort
studies suggest that aspiration and immunodeficiency are risk
factors. In children, educational interventions and efforts to improve adherence to hand hygiene have been associated with decreased VAP rates. More consistent and precise approaches to
the diagnosis of pediatric VAP are needed to better define the
attributable morbidity and mortality, pathophysiology, and appropriate interventions to prevent this disease.
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